HomeComparePINC vs ABBV

PINC vs ABBV: Dividend Comparison 2026

PINC yields 1.49% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $77.3K in total portfolio value
10 years
PINC
PINC
● Live price
1.49%
Share price
$28.26
Annual div
$0.42
5Y div CAGR
16.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.0K
Annual income
$833.94
Full PINC calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PINC vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPINCABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PINC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PINC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PINC
Annual income on $10K today (after 15% tax)
$126.33/yr
After 10yr DRIP, annual income (after tax)
$708.85/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,347.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PINC + ABBV for your $10,000?

PINC: 50%ABBV: 50%
100% ABBV50/50100% PINC
Portfolio after 10yr
$63.7K
Annual income
$12,802.85/yr
Blended yield
20.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PINC
Analyst Ratings
10
Buy
19
Hold
2
Sell
Consensus: Hold
Price Target
$28.25
-0.0% upside vs current
Range: $28.25 — $28.25
Altman Z
0.8
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PINC buys
0
ABBV buys
0
No recent congressional trades found for PINC or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPINCABBV
Forward yield1.49%3.06%
Annual dividend / share$0.42$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR16.4%40.6%
Portfolio after 10y$25.0K$102.3K
Annual income after 10y$833.94$24,771.77
Total dividends collected$4.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$28.25$256.15

Year-by-year: PINC vs ABBV ($10,000, DRIP)

YearPINC PortfolioPINC Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,873$172.99$11,550$430.00$677.00ABBV
2$11,839$204.62$13,472$627.96$1.6KABBV
3$12,910$242.37$15,906$926.08$3.0KABBV
4$14,101$287.51$19,071$1,382.55$5.0KABBV
5$15,430$341.63$23,302$2,095.81$7.9KABBV
6$16,916$406.66$29,150$3,237.93$12.2KABBV
7$18,586$485.01$37,536$5,121.41$18.9KABBV
8$20,466$579.68$50,079$8,338.38$29.6KABBV
9$22,593$694.42$69,753$14,065.80$47.2KABBV
10$25,009$833.94$102,337$24,771.77$77.3KABBV

PINC vs ABBV: Complete Analysis 2026

PINCStock

Premier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates in two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with an access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and workforce solutions. This segment also provides the ASCENDrive programs for members to receive group purchasing programs, tiers, and prices; SURPASS Performance Group services; STOCKD, an e-commerce platform; PROVIDEGX program, which identifies supply sources for drugs that are on or may be at risk of being added to the national drug shortage list, or that are vulnerable to pricing volatility, as well as direct sourcing business; SaaS informatics products; supply chain co-management services; purchased services contracts; direct sourcing solutions; and supply chain resiliency programs. The Performance Services segment provides technology and services platform with offerings that help optimize performance in three main areas, including clinical intelligence, margin improvement, and value-based care under the PINC AI brand; third party administrator services and management of health benefit programs under the Contigo Health brand; and digital invoicing and payables services that offers financial support services to healthcare product suppliers and service providers under the Remitra brand. The company also provides services to other businesses, including food service, schools, and universities. Premier, Inc. was incorporated in 2013 and is headquartered in Charlotte, North Carolina.

Full PINC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PINC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PINC vs SCHDPINC vs JEPIPINC vs OPINC vs KOPINC vs MAINPINC vs JNJPINC vs MRKPINC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.